VIKING GLOBAL INVESTORS LP 13D and 13G filings for Amylyx Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-14 10:24 am Sale |
2023-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
VIKING GLOBAL INVESTORS LP | 2,962,555 4.400% |
-1,672,051 (-36.08%) |
Filing |
| 2023-02-14 1:18 pm Sale |
2022-12-31 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
VIKING GLOBAL INVESTORS LP | 4,634,606 7.000% |
-1,135,930 (-19.68%) |
Filing |
| 2022-09-09 9:50 pm Sale |
2022-09-08 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
VIKING GLOBAL INVESTORS LP | 5,770,536 9.900% |
-1,400,000 (-19.52%) |
Filing |
| 2022-01-21 5:05 pm Purchase |
2022-01-11 | 13G | Amylyx Pharmaceuticals, Inc. AMLX |
VIKING GLOBAL INVESTORS LP | 7,170,536 12.400% |
7,170,536 (New Position) |
Filing |